Cathy Handy Marshall, MD

Dr. Edward Wright is an associate professor of urology at the Johns Hopkins School of Medicine. He serves as the Director of Urology at the Johns Hopkins Bayview Medical Center. His clinical and research interests are in male and female urinary incontinence, complex voiding dysfunction and pelvic genitourinary reconstructive surgery. His specialty has less to do with surgical removal and more with mending urological body parts and restoring functionality in them. His passion for Johns Hopkins lies in the fact that it is the type of place where things can be done, and patients’ questions can be answered and solutions to their problems can be found through all of the resources Johns Hopkins has to offer. Dr. Wright earned his M.D. from Dartmouth Medical School in New Hampshire. He completed his residency in urology at The Presbyterian Hospital in the City of New York and performed a fellowship in Urogynecology at Duke University School of Medicine. Dr. Wright is a member of the American Urologic Association and the Mid-Atlantic Section of American Urologic Association as well as the Society for Urodynamics and Female Urology. He has been recognized with a number of awards including Winner of the Urology Chief Resident's debate New York section of the American Urologic Society at the The New York Academy of Medicine.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer.Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research.Specific research projects include:1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103).2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs;3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs.

Stéphanie Gaillard is a medical oncologist who specializes in the treatment of gynecologic malignancies. She recently joined the faculty of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and is their Director of Gynecologic Cancer Trials. Dr. Gaillard earned her medical degree and doctoral degree in cancer biology from Duke University. Following medical school, she underwent residency training in Internal Medicine and fellowship training in Medical Oncology at the Johns Hopkins School of Medicine. Dr. Gaillard’s research focuses on the development of clinical trials aimed at improving outcomes by incorporating promising new biologic, targeted, and immune therapies into standard treatment regimens. Her translational research program focuses on understanding the immune environment associated with gynecologic cancers and mechanisms of resistance to current therapies.